Company intelligence / Profile preview

EmpowerPharm Inc.

Burlington, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

EmpowerPharm has completed promising Phase 2 clinical trials of its proprietary high-bioavailability CBD oral formulation for social anxiety disorder. The company demonstrated an effective dose of CBD at 300 mg and will use a new high-bioavailability capsule formulation in upcoming Phase 3 studies. The company’s SNEDDS technology improves absorption and therapeutic effect. Regulatory submissions are planned in Canada, the U.S., and internationally with commercial launch preparations underway.

Therapeutic areas: Psychiatry
Modalities: Small molecules (cannabinoid-based, specifically pharmaceutical-grade cannabidiol/CBD)Proprietary oral solid dose formulations (tablets, capsules)
Industry: Biotech

Partnerships

Not specified in public sources.

Beyond the preview

Go deeper on EmpowerPharm Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EmpowerPharm Inc..

Explore the full profile